Skip to main content

Table 1 The characteristics of derivation and validation cohort stratified by renal function recovery

From: Prediction model of renal function recovery for primary membranous nephropathy with acute kidney injury

Characteristics

Derivation cohort (n = 124)

Validation cohort (n = 72)

P

nonrecovery (n = 52)

recovery (n = 72)

nonrecovery (n = 31)

recovery (n = 41)

sex (male), n (%)

43 (82.7)

40 (55.6)

25 (80.6)

27 (65.9)

0.005a

age (yr)

60 ± 10

56 ± 12

62 ± 9

56 ± 13

0.023b

SBP (mmHg)

146 ± 25

141 ± 21

147 ± 23

142 ± 19

0.523

DBP (mmHg)

81 ± 12

82 ± 14

80 ± 12

82 ± 13

0.865

hgb(g/l)

125 ± 21

126 ± 17

122 ± 18

125 ± 17

0.863

glucose (mmol/l)

5.3 ± 1.4

4.9 ± 1.1

4.9 ± 1.2

5.0 ± 1.3

0.383

TC (mmol/l)

8.3 ± 2.4

8.2 ± 2.9

8.0 ± 2.0

7.9 ± 2.9

0.860

TG (mmol/l)

3.3 ± 3.0

3.1 ± 2.1

2.9 ± 1.7

3.2 ± 2.5

0.875

HDL (mmol/l)

1.3 ± 0.4

1.4 ± 1.1

1,3 ± 0.4

1.3 ± 0.6

0.689

LDL (mmol/l)

5.0 ± 2.2

4.8 ± 2.2

4.8 ± 1.7

4.5 ± 2.1

0.660

Scrmax (umol/l)

121 ± 32

111 ± 27

122 ± 34

111 ± 20

0.076

Salb (gl/l)

19.6 ± 3.9

20.7 ± 3.5

19.7 ± 3.7

20.7 ± 3.9

0.239

Upro (g/24 h)

7.3 ± 4.0

6.7 ± 3.3

6.4 ± 2.8

6.9 ± 3.6

0.722

Anti-PLA2R positive,n(%)

49 (94.2)

70 (97.2)

30 (96.8)

41 (100)

0.457

AKI stage, n (%)

 1 stage

37 (71.2)

63 (87.5)

22 (71.0)

39 (95.1)

0.005c

 2 stage

13 (25.0)

8 (11.1)

8 (25.8)

1 (2.4)

0.006d

 3 stage

2 (3.8)

1 (1.4)

1 (3.2)

1 (2.4)

0.849

GBM stage, n (%)

 I stage

40 (76.9)

50 (69.4)

22 (71.0)

30 (73.2)

0.827

 II stage

12 (23.1)

22 (30.6)

9 (29.0)

11 (26.8)

0.827

Infection, n (%)

4 (7.7)

5 (6.9)

3 (9.7)

2 (4.9)

0.886

Thrombosis, n (%)

0 (0)

1 (1.4)

0 (0)

1 (2.4)

0.622

Hypertensive nephropathy, n(%)

41 (78.8)

59 (81.9)

24 (77.4)

33 (80.1)

0.951

Diabetes, n (%)

12 (23.1)

16 (22.2)

7 (29.3)

12 (24.0)

0.848

MPCTX, n (%)

23 (44.2)

44 (61.1)

9 (29.0)

25 (61.0)

0.009e

FK506, n (%)

17 (32.7)

23 (31.9)

10 (32.3)

13 (31.7)

1.000

CSA, n (%)

7 (13.5)

13 (18.1)

4 (12.9)

3 (7.3)

0.462

RSAI, n (%)

48 (92.3)

64 (88.9)

30 (96.8)

37 (90.2)

0.609

Diuretics, n (%)

35 (67.3)

5 (6.9)

20 (64.5)

3 (7.3)

< 0.001f

  1. SBP Systolic blood pressure, DBP Diastolic blood pressure, hbg Hemoglobin, TC Total cholesterol, TG Triglycerides, HDL High-density lipoprotein, LDL Low-density lipoprotein, Salb Serum albumin, Upro Urine protein, GBM Glomerular basement membrane, MPCTX Methylprednisolone with cyclophosphamide, FK506 Tacrolimus, CsA Cyclosporin A, RSAI Renin angiotesin system inhibitors
  2. aDerivation cohort: non-recovery vs recovery, p = 0.022; Validation cohort: non-recovery vs recovery, p = 0.004;
  3. bDerivation cohort: non-recovery vs recovery, p = 0.041; Validation cohort: non-recovery vs recovery, p = 0.024;
  4. cDerivation cohort: non-recovery vs recovery, p = 0.022; Validation cohort: non-recovery vs recovery, p = 0.004
  5. dDerivation cohort: non-recovery vs recovery, p = 0.042; Validation cohort: non-recovery vs recovery, p = 0.003
  6. eDerivation cohort: non-recovery vs recovery, p = 0.063; Validation cohort: non-recovery vs recovery, p = 0.007
  7. fDerivation cohort: non-recovery vs recovery, p < 0.001; Validation cohort: non-recovery vs recovery, p < 0.001